<ѻý>Novel Fixed-Dose Immunotherapy Combo Wins FDA Approvalѻý> Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
<ѻý>Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancerѻý> Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
<ѻý>Novel Therapies Active in Head and Neck Cancersѻý> High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
<ѻý>Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancersѻý> 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
<ѻý>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Upѻý> More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<ѻý>Melanoma Patient on Immunotherapy Develops Severe Dermatitisѻý> Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<ѻý>Long-Term Data Reinforce Standard of Care in Unresectable Melanomaѻý> Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
<ѻý>Case: VEGFR Inhibition in Merkel Cell Carcinoma Patientѻý> Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
<ѻý>FDA Issues Orders Clarifying Rules for Marketing Sunscreensѻý> But more studies on sunscreen chemicals are still needed, advocacy group says Sep 24, 2021
<ѻý>In RA, Little Risk for Recurrent Cancer With Biologic Treatmentѻý> Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
<ѻý>Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanomaѻý> Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
<ѻý>What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor?ѻý> Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
<ѻý>COVID Surges Emerge; FDA Warns About Chantix; Lions, Tigers, Bears Get Vaxxedѻý> A daily roundup of news on COVID-19 and the rest of medicine Jul 06, 2021
<ѻý>Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survivalѻý> News, features, and commentary about cancer-related issues Jun 16, 2021
<ѻý>Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanomaѻý> But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
<ѻý>Lymph Node Findings on PET: Cancer or COVID Vaccine?ѻý> Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<ѻý>Bad Day Sunshine: Benzene Found in Many Sun Care Productsѻý> Valisure also detected the carcinogen in hand sanitizers earlier this year May 26, 2021
<ѻý>Novel Immunotherapy Boosts Melanoma Outcomesѻý> Adding LAG-3 checkpoint inhibitor to nivolumab extended PFS in patients with advanced disease May 19, 2021
<ѻý>Doubling Down on Immunotherapy in Advanced Melanomaѻý> Checkpoint inhibitor combo active after upfront anti-PD-1/L1 therapy May 09, 2021
<ѻý>Op-Ed: Dermatology Needs Lower Costs and Better Careѻý> A proposal for value-based care Apr 21, 2021
<ѻý>Nivolumab Alone Prevails in Resected Melanomaѻý> Adding ipilimumab in adjuvant setting failed to improve relapse-free survival Apr 11, 2021
<ѻý>A Win for Adjuvant Immunotherapy in Esophageal Cancerѻý> And other highlights from the Society of Surgical Oncology's virtual 2021 meeting Mar 31, 2021
<ѻý>Want Data on Recently Approved Actinic Keratosis Drug? Here You Goѻý> Phase III trial now published in full for topical anti-proliferative treatment Feb 10, 2021
<ѻý>First Immunotherapy Approved for Basal Cell Carcinomaѻý> Objective responses in 27% of previously treated patients who received cemiplimab Feb 10, 2021
<ѻý>IL-8 Antibody Active in Tumors After PD-1/L1 Blockadeѻý> Clinical benefit in more than a third of patients with anti-IL-8/nivolumab combo Nov 13, 2020
<ѻý>PD-1 Inhibitor Active in Progressive Basal Cell Cancerѻý> Response rate of 20-30% with cemiplimab after post-hedgehog inhibitor progression or intolerance Nov 11, 2020
<ѻý>Melanoma Survival Benefit Sustained at 5 Years With Adjuvant Comboѻý> Dabrafenib plus trametinib cut relapse risk in half Sep 02, 2020
<ѻý>Demographics Make a Difference in Common Skin Cancersѻý> Study looks at epidemiology of basal versus squamous cell carcinomas Aug 26, 2020
<ѻý>Calcineurin Blockers for Eczema: No Cancer Signal in Big Studyѻý> "Clinicians can use this evidence to counsel and reassure patients" Aug 12, 2020
<ѻý>Triplet OK'd as First-Line Therapy in Melanomaѻý> Immunotherapy plus targeted combo nets FDA approval in BRAF-mutant population Jul 31, 2020
<ѻý>Cancer Immunotherapy Tied to Severe COVID-19 Outcomesѻý> Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<ѻý>Biologics Don't Increase Melanoma Risk... Probablyѻý> Meta-analysis offers some reassurance, but leaves room for doubt May 20, 2020
<ѻý>Face-Aging Selfies Help Modify Risky Skin Behaviors for Teensѻý> Trial looked at effects of a free "UV-selfie" app May 07, 2020
<ѻý>6-Week Keytruda Safe, Effective in Melanomaѻý> Schedule gets FDA approval for all adult indications Apr 30, 2020
<ѻý>Triplet Succeeds in BRAF-Mutant Melanomaѻý> Immunotherapy plus BRAF/MEK inhibition boosts PFS over targeted agents alone Apr 27, 2020
<ѻý>How Prevalent Is Checkpoint Inhibitor Thyroid Dysfunction, Really?ѻý> Real-world data offer word of caution for oncologists Apr 01, 2020
<ѻý>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleedsѻý> Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<ѻý>Staving Off Sepsis; Bleeding and Fibroids: It's Double T Healthwatch!ѻý> This week's topics also include blood levels of sunscreen ingredients, and fish oil and sperm quality Jan 25, 2020 podcast
<ѻý>'Surprising' Number of Cancer Survivors Use Alcoholѻý> Clinicians urged to step up alcohol screening at regular intervals, intervention Jan 22, 2020
<ѻý>What Is Causing This Woman's Swollen Chin?ѻý> A long and challenging diagnostic path with twists and turns Jan 20, 2020